Superior profiling of a number of biomarkers can individualize affected person characterization and empower precision drugs. Typical diagnostic strategies, nonetheless, usually require intensive processing and lack assay versatility and/or multiplexing capability to accommodate completely different biomarkers. To handle these challenges, nucleic acid–protein hybrid nanostructures have emerged as a promising know-how. These hybrids provide multifaceted versatility. On the element stage, they profit from the inherent structural programmability of nucleic acids and the practical versatility of proteins to accommodate various biomarkers; as built-in assemblies, they will function as passive labeling constructs or lively enzymatic machines to satisfy various diagnostic wants. On this overview, we spotlight latest synergistic advances within the molecular configuration and mechanism design of those hybrid techniques to measure a broad spectrum of biomarkers, starting from classical nucleic acid and protein biomarkers to novel modifications and interactions. Lastly, we offer an outlook on rising traits in biomarker discovery and know-how growth that place nucleic acid–protein hybrids as highly effective instruments for precision diagnostics.
